Nobivac^® L4 Questions and Answers

For active immunisation of dogs against L. interrogans and L. kirschneri:

Administer two vaccinations of 1 dose (1 ml) of vaccine with an interval of 4 weeks to dogs from 6 weeks of age onwards.

The first vaccination can be administered from 6 to 9* weeks of age and the second vaccination from 10 to 13 weeks of age.

*In cases of a high level of MDA, first vaccination is recommended at 9 weeks of age.

Duration of immunity: 1 year.

Revaccination: Dogs should be re-vaccinated annually with one dose (1 ml) of vaccine.

The onset of immunity following the second vaccination of the primary course is 3 weeks.

Safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with vaccines in the Nobivac range containing canine distemper virus, canine adenovirus type 2, canine parvovirus (strain 154) and/or canine parainfluenza virus components for subcutaneous administration. The product information of the relevant Nobivac vaccines should be consulted before administration of the mixed product. When mixed with these Nobivac vaccines, the demonstrated safety and efficacy claims for Nobivac L4 are no different from those described for Nobivac L4 alone. When mixed with Nobivac vaccines containing canine parainfluenza virus at annual revaccination, it has been established that there is no interference with the anamnestic response induced by the injectable canine parainfluenza virus component.

Safety and efficacy data are available which demonstrate that this vaccine can be administered on the same day but not mixed with vaccines in the Nobivac range containing Bordetella bronchiseptica and/or parainfluenza virus components for intranasal administration. Safety data are available which demonstrate that this vaccine can be administered at the same time but not mixed with the inactivated vaccine in the Nobivac range against Bordetella bronchiseptica. When this vaccine is administered in association with the inactivated vaccine in the Nobivac range against Bordetella bronchiseptica the demonstrated antibody response data and other immunity data of this vaccine are the same as when this vaccine is administered alone.

Safety and efficacy data are available which demonstrate that this vaccine can be administered at the same time but at different administration sites with vaccine in the Nobivac range against rabies, although this may, in some instances, lead to vomiting.

For simultaneous use 1 dose of a Nobivac vaccine containing canine distemper virus, canine adenovirus type 2, canine parvovirus, and/or canine parainfluenza virus components should be reconstituted with 1 dose (1ml) of Nobivac L4. The mixed vaccines should be at room temperature (15^oC - 25^oC) before they are administered by subcutaneous injection. If Nobivac Rabies is given concurrently with Nobivac L4 then this should not be mixed but should be given as a separate subcutaneous injection at a separate site.

Nobivac L4 can be used during pregnancy.

We do not hold specific data regarding use during lactation and therefore cannot recommend this use during this period.

There are no breed specific contraindications for Nobivac L4.

Nobivac L4 requires storage in a refrigerator between 2 ^oC and 8 ^oC. Do not freeze. Protect from light.